RE:RE:Moderna's CEO Stephan Bancel comments on mRNA cancer vaccine As with CAR-T therapies, significant issues with "personalized mRNA vaccines" of scalability, affordability, and accessibility of personalized cancer vaccines to patients, especially in emerging markets, are complexities of these therapies that are not faced by ONCY's pelareorep in combination with an immune checkpoint inhibitors or other I/O agents.
Manufacturing and delivery are valid concerns for any potential cancer vaccine contenders. For example, Dendreon's FDA approved Provenge was never widely adopted partly because of its complicated treatment process in the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistance (hormone-refractory) prostate cancer.